Cipla Limited has announced the opening of a special window for the lodgement of transfer and dematerialisation of physical shares, following a directive from the Securities and Exchange Board of India (SEBI). This initiative provides eligible shareholders with an opportunity to convert their physical share certificates to electronic form and complete pending transfer processes.

SEBI Directive and Timeline

The pharmaceutical company issued the notice pursuant to SEBI Circular No. HO/3R/11/2026-MIRSD-PODI/37/50/2026 dated January 30, 2026. The special window will remain operational until February 4, 2027, giving shareholders nearly a year to complete their transfer and dematerialisation requirements.

Eligibility Criteria

Cipla has provided a detailed matrix outlining the eligibility conditions for shareholders to utilise this special window:

Exclusions and Restrictions

The company has specified that certain cases will not be considered under this special window:

• Cases involving disputes between transferor and transferee
• Shares which have been transferred to Investor Education and Protection Fund (IEPF)

Lock-in Period and Conditions

Shares lodged for transfer pursuant to this circular will be issued exclusively in dematerialised form and will be subject to a lock-in period of one year from the date of registration of transfer. During this lock-in period, such shares cannot be transferred or pledged.

Process and Contact Information

Eligible shareholders wishing to avail this opportunity must submit requisite documents to KFIN Technologies Limited, the company's Registrar and Share Transfer Agent. The documents should be sent to their Hyderabad office located at Selenium Tower B, Plot No. 31 & 32, Gachibowli, Nanakramguda, Serilingampally, Hyderabad, Telangana - 500 032.

For queries, shareholders can raise service requests at sivward@cskinfotech.com or cossecretary@cipla.com . The company has encouraged shareholders to take advantage of this special window introduced in their interest.

Cipla has informed stock exchanges about the resignation of a key executive from its leadership team. The pharmaceutical company announced that Mr. Pradeep Bhadauria, Global Chief Scientific Officer, will be leaving the organization to pursue opportunities outside the company.

Executive Departure Details

The resignation announcement provides specific details about Bhadauria's departure from the pharmaceutical giant:

Regulatory Communication

Cipla filed the resignation notice on March 26, 2026, through proper regulatory channels. The announcement was simultaneously communicated to multiple stock exchanges where the company's shares are listed. Company Secretary Rajendra Chopra signed the official communication, ensuring compliance with disclosure requirements.

Leadership Structure Impact

Bhadauria held dual responsibilities within Cipla's organizational structure. As Global Chief Scientific Officer, he was responsible for the company's scientific strategy and research initiatives. Additionally, his role as a member of the Management Council positioned him as part of the senior leadership team involved in strategic decision-making processes.

The executive's employment through Cipla USA Inc., a wholly owned subsidiary, reflects the company's global operational structure. This arrangement allows Cipla to manage its international operations while maintaining oversight of key personnel across different geographical locations.

Transition Timeline

The resignation becomes effective on March 31, 2026, providing the company with a defined timeline for transition planning. This advance notice allows Cipla to manage the leadership change systematically and ensure continuity in its scientific operations and strategic initiatives.